CD274 and neoplasm: Currently, available evidence indicates that PD-L1, tumor mutational burden (TMB), and microsatellite instability (MSI)/mismatched repair-deficient (MMR) have been acknowledged for screening the population in whom immunotherapy is effective of immune drugs (43–45).